Journal
Mounjaro vs Zepbound: One Tirzepatide, Two Labels, and the Channel That Matters
Released: Last reviewed:
The short answer
Identical molecule, two regulatory costumes: Mounjaro and Zepbound are both Eli Lilly's tirzepatide, sharing the same 2.5-to-15 mg weekly dose ladder. The split: Mounjaro carries the type 2 diabetes indication; Zepbound carries chronic weight management plus — since December 2024 — moderate-to-severe obstructive sleep apnea in adults with obesity. The consequences follow the labels exactly as on the semaglutide side: coverage — Mounjaro rides diabetes formularies with a T2D diagnosis; Zepbound rides weight and OSA coverage, using the sleep-apnea door where weight-drug carve-outs block; and cash — the channel this site benchmarks constantly, LillyDirect's $299/$399/$449 vial program with its 45-day rule, is Zepbound-only. Practical routing: T2D diagnosis → Mounjaro via coverage; weight or OSA → Zepbound, insured where possible, LillyDirect cash where not — and "Mounjaro for weight loss" as a cash plan runs into the same off-label coverage wall as its Ozempic cousin.
The details worth knowing
Switching between the names is pharmacologically trivial and administratively real — same molecule means a coverage-driven swap (diagnosis changes, plan changes, cash pivot) maps dose-for-dose, handled by the prescriber as paperwork rather than re-titration. The OSA indication is Zepbound's quiet superpower: it's a second coverage argument (indication-specific prior authorizations through weight-exclusion plans) and the reason a diagnosed-apnea patient should never accept a cash-only framing before the coverage attempt. The dose-ladder economics differ by channel, not by name: LillyDirect's vials price by dose (which the brand-versus-compounded math weighs against the flat compounded tier), while covered product prices by copay regardless of milligrams — one more reason the insured path outranks everything when it exists. And the compounded footnote mirrors the semaglutide page: compounded "tirzepatide" ($125–$179 in the credible tier) is made with the drug in Mounjaro and Zepbound, not the same product, with neither label, no finished-product FDA review, and the full verification homework — a fourth door, not a third brand. One molecule, two names, four doors; the diagnosis picks the name, and the budget picks the door.
Questions people ask
Are Mounjaro and Zepbound the same drug?
Same molecule — Eli Lilly's tirzepatide, same 2.5–15 mg weekly ladder — with different labels: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and (since December 2024) obstructive sleep apnea with obesity. Insurance and cash channels follow the labels.
Can I buy Mounjaro through LillyDirect's vial program?
No — the $299/$399/$449 self-pay vial program (45-day refill rule) is Zepbound-only. Mounjaro's economics run through diabetes coverage with a T2D diagnosis; cash tirzepatide for weight routes to Zepbound's channels or the compounded market with its verification homework.
Which is easier to get covered — Mounjaro or Zepbound?
Whichever matches your diagnosis: T2D makes Mounjaro the covered path on diabetes formularies; without diabetes, Zepbound's weight indication — and especially its sleep-apnea indication, filed with the sleep study — is the coverage argument. Off-label Mounjaro for weight typically fails the plan audit.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.